Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
24 hedge funds and large institutions have $3.99M invested in Intellipharmaceuticals International Inc. in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0% more funds holding
Funds holding: 24 → 24 (0)
37% less capital invested
Capital invested by funds: $6.31M → $3.99M (-$2.32M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$16.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$11.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
| 4 |
Barclays
London,
United Kingdom
|
+$7.15K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.21M |
| 2 |
VF
Virtu Financial
New York
|
-$35K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$17K |
| 4 |
Morgan Stanley
New York
|
-$15.2K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$13.8K |
IPCI Hedge Fund Activity: Q2 2018 in Review
24 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q2 2018, worth a combined $3.99M — down 37% from $6.31M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IPCI positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $16.9K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.21M sold.
- 24 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $3.99M of Intellipharmaceuticals International Inc. stock for Q2 2018, down 37% quarter-over-quarter.
- 5 funds opened new Intellipharmaceuticals International Inc. positions in Q2 2018 and 4 closed out, a net change of +1 holder.
- The largest Intellipharmaceuticals International Inc. buyer in Q2 2018 was Boothbay Fund Management, an estimated $16.9K added.
- The largest Intellipharmaceuticals International Inc. seller in Q2 2018 was Anson Funds Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2018.